Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Gross Margin
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
|
23.4B CNY |
46%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
709B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
370B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
200.7B CHF |
73%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
180.5B CHF |
75%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
160B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
199.6B USD |
81%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
68%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
114.6B EUR |
70%
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, rooted in the rich tapestry of traditional Chinese medicine, has carved out a substantial presence in the pharmaceutical industry. Established in a region known for its deep cultural heritage in holistic healing, the company seamlessly weaves ancient practices with modern scientific advancements. At the core of its operations, Da Ren Tang specializes in the research, development, production, and distribution of traditional Chinese medicine and pharmaceuticals. Beyond just leveraging ancient recipes, the company invests significantly in cutting-edge research to validate and enhance the efficacy of its formulations, gaining trust not only domestically but also in international markets. This blending of tradition and innovation enables Da Ren Tang to capture a diverse customer base, ranging from individuals seeking natural remedies to medical institutions incorporating holistic approaches into patient care. The economic engine of Da Ren Tang powers through a multi-faceted monetization strategy. It manufactures a broad portfolio of pharmaceutical products, including patented Chinese medicines and active pharmaceutical ingredients (APIs), which are distributed through a well-established network of pharmacies and healthcare providers. Additionally, the company has embraced the digital era by exploring e-commerce platforms, thereby expanding its reach and accessibility to tech-savvy consumers globally. By maintaining stringent quality controls and adopting sustainable practices in its production processes, Da Ren Tang not only enhances its reputation but also adheres to evolving regulatory standards worldwide. Such strategic positioning allows the company to capitalize on the growing global interest in traditional medicines, contributing significantly to its revenue streams and reinforcing its status as a prominent player in the pharmaceutical landscape.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's most recent financial statements, the company has Gross Margin of 45.8%.
You don't have any saved screeners yet